Incidence of glaucoma surgeries related to anti-VEGF injections
My Session Status
Authors: Natalia Maes, John Liu, Steven Schendel, Gavin Docherty, Carol Tadrous
Author
Disclosure Block: N. Maes: None. J. Liu: None. S.
Schendel: None. G. Docherty: None. C.
Tadrous: None.
Abstract
Body:
Purpose: To
highlight the elevated number of Glaucoma surgeries related to the use of
intravitreal antivascular endothelial growth factor (anti-VEGF) over a period
of 18 months (from January/2016 to July/2017), under the care of one glaucoma
surgeon in Vancouver, British Columbia.
Study Design: Observational-descriptive-case series
Methods: All Glaucoma surgeries performed during this period were
retrospectively reviewed. The patients who were undergoing intravitreal
Anti-VEGF treatment at the time of surgery were included in this analysis.
Those who developed Neovascular Glaucoma or required intravitreal steroid, at any
point over 18 months, were excluded. Patient’s age and gender were collected,
as well as lens status, previous diagnosis of Glaucoma, previous SLT (selective
laser trabeculoplasty), glaucoma surgery performed, subtype of anti-VEGF and
retinal disease. The mean drops required for pressure treatment, visual acuity
and intraocular pressure (IOP) before, 6 and 12 months after the surgery were
also assessed.
Results: A total of 430 Glaucoma surgeries were performed. From
which 121 (28.14%) were carried out in the context of anti-VEGF treatment. The
mean age of the subjects was 75.61 years. The mean interval time between the
first consult with the glaucoma specialist and the date of surgery was 3.8
months. Of the cases, 41 (33.88%) were previously known to have glaucoma or
were glaucoma suspects and 80 (66.11%) did not have glaucoma or ocular
hypertension before starting the Anti-VEGF treatment. The mean IOP before
surgery was 37.18 mmHg. There was a decline of 63.28% after 12 months, leading
to a final mean pressure of 13.65 mmHg.
Conclusions: A surprisingly elevated rate of Glaucoma surgeries has been observed among patients on anti-VEGF treatment in Vancouver. To the best of our knowledge, this inflated number of surgeries has not been reported worldwide. Additional data on Visual outcomes and Visual Fields are being collected.